Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diffuse Large B-Cell Lymphoma-Pipeline Review, H1 2015

Diffuse Large B-Cell Lymphoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diffuse Large B-Cell Lymphoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma-Pipeline Review, H1 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Diffuse Large B-Cell Lymphoma Overview 11

Therapeutics Development 12

Pipeline Products for Diffuse Large B-Cell Lymphoma-Overview 12

Pipeline Products for Diffuse Large B-Cell Lymphoma-Comparative Analysis 13

Diffuse Large B-Cell Lymphoma-Therapeutics under Development by Companies 14

Diffuse Large B-Cell Lymphoma-Therapeutics under Investigation by Universities/Institutes 20

Diffuse Large B-Cell Lymphoma-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Diffuse Large B-Cell Lymphoma-Products under Development by Companies 24

Diffuse Large B-Cell Lymphoma-Products under Investigation by Universities/Institutes 32

Diffuse Large B-Cell Lymphoma-Companies Involved in Therapeutics Development 33

AbbVie Inc. 33

Affimed Therapeutics AG 34

Amgen Inc. 35

Aprogen, Inc. 36

Arrien Pharmaceuticals, LLC 37

Astellas Pharma Inc. 38

AstraZeneca Plc 39

Aurigene Discovery Technologies Limited 40

Bayer AG 41

BIND Therapeutics, Inc. 42

Biocon Limited 43

Boehringer Ingelheim GmbH 44

Bristol-Myers Squibb Company 45

Celgene Corporation 46

Cell>Point, L.L.C. 47

Cellular Biomedicine Group, Inc. 48

Constellation Pharmaceuticals, Inc. 49

CTI BioPharma Corp. 50

CureTech Ltd. 51

Curis, Inc. 52

Eisai Co., Ltd. 53

EpiZyme, Inc. 54

Erytech Pharma SA 55

F. Hoffmann-La Roche Ltd. 56

Genentech, Inc. 57

Gilead Sciences, Inc. 58

GlaxoSmithKline Plc 59

Idera Pharmaceuticals, Inc. 60

ImmunoGen, Inc. 61

Immunomedics, Inc. 62

Immunovaccine, Inc. 63

Incyte Corporation 64

Infinity Pharmaceuticals, Inc. 65

Johnson & Johnson 66

Karus Therapeutics Limited 67

Karyopharm Therapeutics, Inc. 68

Kite Pharma, Inc. 69

Mabion SA 70

MedImmune, LLC 71

Merck & Co., Inc. 72

Millennium Pharmaceuticals, Inc. 73

Mirati Therapeutics Inc. 74

Mirna Therapeutics, Inc. 75

Molplex Ltd. 76

MorphoSys AG 77

Nimbus Therapeutics, LLC 78

Nordic Nanovector AS 79

Novartis AG 80

Ono Pharmaceutical Co., Ltd. 81

Onyx Pharmaceuticals, Inc. 82

Pfizer Inc. 83

Pharmacyclics, Inc. 84

Philogen S.p.A. 85

Portola Pharmaceuticals, Inc. 86

Priaxon AG 87

ProNAi Therapeutics, Inc. 88

RedHill Biopharma Ltd. 89

Redx Pharma Ltd 90

Respiratorius AB 91

Rhizen Pharmaceuticals SA 92

Sandoz International GmbH 93

Seattle Genetics, Inc. 94

Taiho Pharmaceutical Co., Ltd. 95

TG Therapeutics, Inc. 96

Diffuse Large B-Cell Lymphoma-Therapeutics Assessment 97

Assessment by Monotherapy Products 97

Assessment by Combination Products 98

Assessment by Target 99

Assessment by Mechanism of Action 103

Assessment by Route of Administration 107

Assessment by Molecule Type 109

Drug Profiles 111

187Re-EC-G-Drug Profile 111

490-PXN-Drug Profile 112

ABC-294640-Drug Profile 113

acalisib-Drug Profile 115

ACP-196-Drug Profile 116

AFM-11-Drug Profile 118

AFM-13-Drug Profile 119

alisertib-Drug Profile 120

ARN-3236-Drug Profile 124

ASN-002-Drug Profile 125

asparaginase-Drug Profile 126

atezolizumab-Drug Profile 128

azacitidine-Drug Profile 131

AZD-2811-Drug Profile 134

AZD-3965-Drug Profile 135

AZD-9150-Drug Profile 137

bendamustine hydrochloride-Drug Profile 138

Betalutin-Drug Profile 141

BI-836826-Drug Profile 143

blinatumomab-Drug Profile 144

BLyS-gel-Drug Profile 147

BMS-986016-Drug Profile 148

bortezomib-Drug Profile 149

brentuximab vedotin-Drug Profile 154

buparlisib hydrochloride-Drug Profile 160

BVX-20-Drug Profile 164

carfilzomib-Drug Profile 165

CBM-C19.1-Drug Profile 169

CBM-C20.1-Drug Profile 170

CC-122-Drug Profile 171

CC-223-Drug Profile 173

Cell Therapy for Oncology-Drug Profile 174

Cell Therapy to Target CD19 for Oncology-Drug Profile 175

cerdulatinib-Drug Profile 176

coltuximab ravtansine-Drug Profile 177

copanlisib hydrochloride-Drug Profile 179

CPI-0610-Drug Profile 183

CPI-169-Drug Profile 184

CUDC-427-Drug Profile 185

CUDC-907-Drug Profile 186

daratumumab-Drug Profile 188

Darleukin-Drug Profile 191

denintuzumab mafodotin-Drug Profile 193

DPX-Survivac-Drug Profile 194

duvelisib-Drug Profile 197

E-6438-Drug Profile 200

E-7449-Drug Profile 202

epacadostat-Drug Profile 203

epratuzumab-Drug Profile 205

everolimus-Drug Profile 210

GS-5829-Drug Profile 216

GS-9973-Drug Profile 217

GSK-2816126-Drug Profile 218

ibrutinib-Drug Profile 219

idelalisib-Drug Profile 225

IMGN-529-Drug Profile 228

IMO-8400-Drug Profile 230

inotuzumab ozogamicin-Drug Profile 232

IT-901-Drug Profile 234

JNJ-64052781-Drug Profile 235

KA-2237-Drug Profile 236

KTE-C19 CAR-Drug Profile 237

lenalidomide-Drug Profile 239

MEDI-0680-Drug Profile 243

MEDI-551-Drug Profile 244

MK-2206-Drug Profile 246

MK-8628-Drug Profile 249

mocetinostat-Drug Profile 251

Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors-Drug Profile 254

MOR-208-Drug Profile 255

moxetumomab pasudotox-Drug Profile 257

MRX-34-Drug Profile 259

NBD Peptide-Drug Profile 261

ND-2110-Drug Profile 263

ND-2158-Drug Profile 265

nivolumab-Drug Profile 267

obinutuzumab-Drug Profile 273

pecazine-Drug Profile 276

pembrolizumab-Drug Profile 277

pidilizumab-Drug Profile 284

pixantrone dimaleate-Drug Profile 286

PNT-2258-Drug Profile 290

polatuzumab vedotin-Drug Profile 292

PRT-060318-Drug Profile 294

Pt-EC-G-Drug Profile 295

rituximab biosimilar-Drug Profile 296

rituximab biosimilar-Drug Profile 297

rituximab biosimilar-Drug Profile 298

rituximab biosimilar-Drug Profile 300

rituximab biosimilar-Drug Profile 301

romidepsin-Drug Profile 302

RP-6530-Drug Profile 305

ruxolitinib phosphate-Drug Profile 306

selinexor-Drug Profile 311

SGN-CD70A-Drug Profile 316

SH-7129-Drug Profile 317

Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders-Drug Profile 319

Small Molecule to Inhibit IRAK-4 Cancer and Inflammation-Drug Profile 320

Small Molecules for Diffuse Large B Cell Lymphoma-Drug Profile 321

Small Molecules to Inhibit IRAK4 for Immunology and Oncology-Drug Profile 322

Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma-Drug Profile 323

sotrastaurin acetate-Drug Profile 324

spebrutinib besylate-Drug Profile 326

Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia-Drug Profile 328

TAK-659-Drug Profile 329

TAS-5567-Drug Profile 330

tisagenlecleucel-T-Drug Profile 331

ublituximab [INN] + TGR-1202-Drug Profile 333

ulocuplumab-Drug Profile 334

urelumab-Drug Profile 336

valproate sodium-Drug Profile 338

venetoclax-Drug Profile 339

vorinostat-Drug Profile 342

Diffuse Large B-Cell Lymphoma-Recent Pipeline Updates 346

Diffuse Large B-Cell Lymphoma-Dormant Projects 549

Diffuse Large B-Cell Lymphoma-Discontinued Products 551

Diffuse Large B-Cell Lymphoma-Product Development Milestones 553

Featured News & Press Releases 553

Appendix 560

Methodology 560

Coverage 560

Secondary Research 560

Primary Research 560

Expert Panel Validation 560

Contact Us 560

Disclaimer 561

List of Tables

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015 20

Number of Products under Development for Diffuse Large B-Cell Lymphoma-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Development, H1 2015 31

Products under Development by Companies, H1 2015 32

Products under Development by Companies, H1 2015 (Contd..1) 33

Products under Development by Companies, H1 2015 (Contd..2) 34

Products under Development by Companies, H1 2015 (Contd..3) 35

Products under Development by Companies, H1 2015 (Contd..4) 36

Products under Development by Companies, H1 2015 (Contd..5) 37

Products under Development by Companies, H1 2015 (Contd..6) 38

Products under Development by Companies, H1 2015 (Contd..7) 39

Products under Investigation by Universities/Institutes, H1 2015 40

Diffuse Large B-Cell Lymphoma-Pipeline by AbbVie Inc., H1 2015 41

Diffuse Large B-Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 42

Diffuse Large B-Cell Lymphoma-Pipeline by Amgen Inc., H1 2015 43

Diffuse Large B-Cell Lymphoma-Pipeline by Aprogen, Inc., H1 2015 44

Diffuse Large B-Cell Lymphoma-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 45

Diffuse Large B-Cell Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 46

Diffuse Large B-Cell Lymphoma-Pipeline by AstraZeneca Plc, H1 2015 47

Diffuse Large B-Cell Lymphoma-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 48

Diffuse Large B-Cell Lymphoma-Pipeline by Bayer AG, H1 2015 49

Diffuse Large B-Cell Lymphoma-Pipeline by BIND Therapeutics, Inc., H1 2015 50

Diffuse Large B-Cell Lymphoma-Pipeline by Biocon Limited, H1 2015 51

Diffuse Large B-Cell Lymphoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 52

Diffuse Large B-Cell Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 53

Diffuse Large B-Cell Lymphoma-Pipeline by Celgene Corporation, H1 2015 54

Diffuse Large B-Cell Lymphoma-Pipeline by Cell>Point, L.L.C., H1 2015 55

Diffuse Large B-Cell Lymphoma-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 56

Diffuse Large B-Cell Lymphoma-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 57

Diffuse Large B-Cell Lymphoma-Pipeline by CTI BioPharma Corp., H1 2015 58

Diffuse Large B-Cell Lymphoma-Pipeline by CureTech Ltd., H1 2015 59

Diffuse Large B-Cell Lymphoma-Pipeline by Curis, Inc., H1 2015 60

Diffuse Large B-Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 61

Diffuse Large B-Cell Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 62

Diffuse Large B-Cell Lymphoma-Pipeline by Erytech Pharma SA, H1 2015 63

Diffuse Large B-Cell Lymphoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 64

Diffuse Large B-Cell Lymphoma-Pipeline by Genentech, Inc., H1 2015 65

Diffuse Large B-Cell Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 66

Diffuse Large B-Cell Lymphoma-Pipeline by GlaxoSmithKline Plc, H1 2015 67

Diffuse Large B-Cell Lymphoma-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 68

Diffuse Large B-Cell Lymphoma-Pipeline by ImmunoGen, Inc., H1 2015 69

Diffuse Large B-Cell Lymphoma-Pipeline by Immunomedics, Inc., H1 2015 70

Diffuse Large B-Cell Lymphoma-Pipeline by Immunovaccine, Inc., H1 2015 71

Diffuse Large B-Cell Lymphoma-Pipeline by Incyte Corporation, H1 2015 72

Diffuse Large B-Cell Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 73

Diffuse Large B-Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 74

Diffuse Large B-Cell Lymphoma-Pipeline by Karus Therapeutics Limited, H1 2015 75

Diffuse Large B-Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 76

Diffuse Large B-Cell Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 77

Diffuse Large B-Cell Lymphoma-Pipeline by Mabion SA, H1 2015 78

Diffuse Large B-Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 79

Diffuse Large B-Cell Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 80

Diffuse Large B-Cell Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 81

Diffuse Large B-Cell Lymphoma-Pipeline by Mirati Therapeutics Inc., H1 2015 82

Diffuse Large B-Cell Lymphoma-Pipeline by Mirna Therapeutics, Inc., H1 2015 83

Diffuse Large B-Cell Lymphoma-Pipeline by Molplex Ltd., H1 2015 84

Diffuse Large B-Cell Lymphoma-Pipeline by MorphoSys AG, H1 2015 85

Diffuse Large B-Cell Lymphoma-Pipeline by Nimbus Therapeutics, LLC, H1 2015 86

Diffuse Large B-Cell Lymphoma-Pipeline by Nordic Nanovector AS, H1 2015 87

Diffuse Large B-Cell Lymphoma-Pipeline by Novartis AG, H1 2015 88

Diffuse Large B-Cell Lymphoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 89

Diffuse Large B-Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 90

Diffuse Large B-Cell Lymphoma-Pipeline by Pfizer Inc., H1 2015 91

Diffuse Large B-Cell Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 92

Diffuse Large B-Cell Lymphoma-Pipeline by Philogen S.p.A., H1 2015 93

Diffuse Large B-Cell Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 94

Diffuse Large B-Cell Lymphoma-Pipeline by Priaxon AG, H1 2015 95

Diffuse Large B-Cell Lymphoma-Pipeline by ProNAi Therapeutics, Inc., H1 2015 96

Diffuse Large B-Cell Lymphoma-Pipeline by RedHill Biopharma Ltd., H1 2015 97

Diffuse Large B-Cell Lymphoma-Pipeline by Redx Pharma Ltd, H1 2015 98

Diffuse Large B-Cell Lymphoma-Pipeline by Respiratorius AB, H1 2015 99

Diffuse Large B-Cell Lymphoma-Pipeline by Rhizen Pharmaceuticals SA, H1 2015 100

Diffuse Large B-Cell Lymphoma-Pipeline by Sandoz International GmbH, H1 2015 101

Diffuse Large B-Cell Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 102

Diffuse Large B-Cell Lymphoma-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 103

Diffuse Large B-Cell Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 104

Assessment by Monotherapy Products, H1 2015 105

Assessment by Combination Products, H1 2015 106

Number of Products by Stage and Target, H1 2015 108

Number of Products by Stage and Mechanism of Action, H1 2015 112

Number of Products by Stage and Route of Administration, H1 2015 116

Number of Products by Stage and Molecule Type, H1 2015 118

Diffuse Large B-Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 354

Diffuse Large B-Cell Lymphoma-Dormant Projects, H1 2015 557

Diffuse Large B-Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 558

Diffuse Large B-Cell Lymphoma-Discontinued Products, H1 2015 559

Diffuse Large B-Cell Lymphoma-Discontinued Products (Contd..1), H1 2015 560

List of Figures

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015 20

Number of Products under Development for Diffuse Large B-Cell Lymphoma-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Products, H1 2015 31

Assessment by Monotherapy Products, H1 2015 105

Number of Products by Top 10 Targets, H1 2015 107

Number of Products by Stage and Top 10 Targets, H1 2015 107

Number of Products by Top 10 Mechanism of Actions, H1 2015 111

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 111

Number of Products by Top 10 Routes of Administration, H1 2015 115

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 115

Number of Products by Top 10 Molecule Types, H1 2015 117

Number of Products by Stage and Top 10 Molecule Types, H1 2015 117

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Affimed Therapeutics AG

Amgen Inc.

Aprogen, Inc.

Arrien Pharmaceuticals, LLC

Astellas Pharma Inc.

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Bayer AG

BIND Therapeutics, Inc.

Biocon Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cell>Point, L.L.C.

Cellular Biomedicine Group, Inc.

Constellation Pharmaceuticals, Inc.

CTI BioPharma Corp.

CureTech Ltd.

Curis, Inc.

Eisai Co., Ltd.

EpiZyme, Inc.

Erytech Pharma SA

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Immunovaccine, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Johnson & Johnson

Karus Therapeutics Limited

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

Mabion SA

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Mirna Therapeutics, Inc.

Molplex Ltd.

MorphoSys AG

Nimbus Therapeutics, LLC

Nordic Nanovector AS

Novartis AG

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Pfizer Inc.

Pharmacyclics, Inc.

Philogen S.p.A.

Portola Pharmaceuticals, Inc.

Priaxon AG

ProNAi Therapeutics, Inc.

RedHill Biopharma Ltd.

Redx Pharma Ltd

Respiratorius AB

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Seattle Genetics, Inc.

Taiho Pharmaceutical Co., Ltd.

TG Therapeutics, Inc.

Diffuse Large B-Cell Lymphoma Therapeutic Products under Development, Key Players in Diffuse Large B-Cell Lymphoma Therapeutics, Diffuse Large B-Cell Lymphoma Pipeline Overview, Diffuse Large B-Cell Lymphoma Pipeline, Diffuse Large B-Cell Lymphoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com